Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Merck belongs to, so it often moves with news about it.
- LLY Eli Lilly and
Eli Lilly and is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson
Johnson & Johnson is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie
AbbVie is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories
Abbott Laboratories is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
- VRTX Vertex Pharmaceuticals
Vertex Pharmaceuticals is a peer of Merck in pharmaceutical preparations; rivals often move on the same news.
- AMGN Amgen
Amgen is a peer of Moderna in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences
Gilead Sciences is a peer of Moderna in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| MRNA | -5.90% | +0.84% | base | +3.40% | +16.98% | +9.28% | +19.24% |
| PFE | -3.00% | -2.47% | base | -2.38% | +0.26% | -2.70% | -4.31% |
| MRK | -4.45% | -1.43% | base | -2.55% | +1.29% | -0.75% | -1.14% |
| XLV | -2.95% | -0.31% | base | -0.34% | +2.73% | +0.31% | +0.13% |
| LLY | -9.22% | -2.71% | base | -0.17% | +0.45% | -2.64% | -4.04% |
| JNJ | -0.68% | +1.70% | base | -1.63% | +2.13% | +0.67% | +2.13% |
| ABBV | -0.84% | +0.67% | base | -1.01% | +1.62% | +0.12% | +0.94% |
| ABT | -6.49% | -5.19% | base | -0.80% | +5.08% | +2.96% | -0.28% |
| VRTX | -5.88% | -2.43% | base | -4.08% | -0.81% | -1.98% | -1.19% |
| AMGN | -3.75% | -1.04% | base | -0.92% | +2.72% | -1.06% | -0.89% |
| GILD | -6.65% | -2.82% | base | -1.70% | +2.38% | -1.69% | -1.64% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | -1.01% | final price |
| ABBV | the next day | +1.62% | final price |
| ABBV | two days later | +0.12% | final price |
| ABBV | three days later | +0.94% | final price |
| ABBV | three days earlier | +0.67% | final price |
| ABBV | five days earlier | -0.84% | final price |
| ABT | that day | -0.80% | final price |
| ABT | the next day | +5.08% | final price |
| ABT | two days later | +2.96% | final price |
| ABT | three days later | -0.28% | final price |
| ABT | three days earlier | -5.19% | final price |
| ABT | five days earlier | -6.49% | final price |
| AMGN | that day | -0.92% | final price |
| AMGN | the next day | +2.72% | final price |
| AMGN | two days later | -1.06% | final price |
| AMGN | three days later | -0.89% | final price |
| AMGN | three days earlier | -1.04% | final price |
| AMGN | five days earlier | -3.75% | final price |
| GILD | that day | -1.70% | final price |
| GILD | the next day | +2.38% | final price |
| GILD | two days later | -1.69% | final price |
| GILD | three days later | -1.64% | final price |
| GILD | three days earlier | -2.82% | final price |
| GILD | five days earlier | -6.65% | final price |
| JNJ | that day | -1.63% | final price |
| JNJ | the next day | +2.13% | final price |
| JNJ | two days later | +0.67% | final price |
| JNJ | three days later | +2.13% | final price |
| JNJ | three days earlier | +1.70% | final price |
| JNJ | five days earlier | -0.68% | final price |
| LLY | that day | -0.17% | final price |
| LLY | the next day | +0.45% | final price |
| LLY | two days later | -2.64% | final price |
| LLY | three days later | -4.04% | final price |
| LLY | three days earlier | -2.71% | final price |
| LLY | five days earlier | -9.22% | final price |
| MRK | that day | -2.55% | final price |
| MRK | the next day | +1.29% | final price |
| MRK | two days later | -0.75% | final price |
| MRK | three days later | -1.14% | final price |
| MRK | three days earlier | -1.43% | final price |
| MRK | five days earlier | -4.45% | final price |
| MRNA | that day | +3.40% | final price |
| MRNA | the next day | +16.98% | final price |
| MRNA | two days later | +9.28% | final price |
| MRNA | three days later | +19.24% | final price |
| MRNA | three days earlier | +0.84% | final price |
| MRNA | five days earlier | -5.90% | final price |
| PFE | that day | -2.38% | final price |
| PFE | the next day | +0.26% | final price |
| PFE | two days later | -2.70% | final price |
| PFE | three days later | -4.31% | final price |
| PFE | three days earlier | -2.47% | final price |
| PFE | five days earlier | -3.00% | final price |
| VRTX | that day | -4.08% | final price |
| VRTX | the next day | -0.81% | final price |
| VRTX | two days later | -1.98% | final price |
| VRTX | three days later | -1.19% | final price |
| VRTX | three days earlier | -2.43% | final price |
| VRTX | five days earlier | -5.88% | final price |
| XLV | that day | -0.34% | final price |
| XLV | the next day | +2.73% | final price |
| XLV | two days later | +0.31% | final price |
| XLV | three days later | +0.13% | final price |
| XLV | three days earlier | -0.31% | final price |
| XLV | five days earlier | -2.95% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Gilbert Cisneros bought Moderna (MRNA), worth $1,001 - $15,000 on 20 Oct 2026. That is 14 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 74 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 14 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 27 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial” scores 12 out of 100. The score uses 1 sources.